Search - tctmd.com

Displaying 61 - 80 of 117

Sort: Relevancy | Date

Presentation TCT 2017

Risk Score Development, Validation, Precision, Discrimination, and Utility

Presenter: Robert A. Harrington, Sanjay Kaul, Davide Capodanno

October 30, 2017

Presentation TCT 2017

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

Presenter: Robert A. Harrington, Sanjay Kaul, Giuseppe Biondi-Zoccai

October 30, 2017

Presentation TCT 2017

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

Presenter: Robert A. Harrington, Sanjay Kaul, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

The Worst Misinterpretations Ive Seen in Observational Research Studies: How to Spot Them, How to Avoid Them

Presenter: Robert A. Harrington, Sanjay Kaul

October 30, 2017

Presentation TCT 2017

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Sanjay Kaul

October 30, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

Presentation TCT 2016

Opening Salvo: Despite EXCEL And NOBLE, I Don't Believe PCI Should Be the Standard Revascularization Strategy for Most Patients With Left Main CAD!

Presenter: Sanjay Kaul, Jeffrey J. Popma, John D. Puskas

November 01, 2016

Presentation TCT 2016

Return Fire: The Contrarian View - Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Presenter: Sanjay Kaul, Jeffrey J. Popma, Michael Haude

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Presenter: Sanjay Kaul, Jeffrey J. Popma, Salvatore Cassese

November 01, 2016

Presentation TCT 2016

Subgroup Analyses: How Useful or Harmful Are They?

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, Sanjay Kaul

November 01, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy Clinical Trial Design

Presenter: C. Michael Gibson, Daniel I. Simon, Sanjay Kaul

October 30, 2016

News Daily News

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

News Daily News

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Michael O'Riordan

March 09, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

Michael O'Riordan

March 09, 2016

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

Advertisement

Risk Score Development, Validation, Precision, Discrimination, and Utility

Do Patients Really Do Better When Their Cardiologists Are Away at Conferences? Embedding Controls in Observational Studies

Assessment of the Quality and Reliability of Meta-analysis (Summary Level, Network, and Individual Patient Data-Based)

Natures Randomized Trials: Natural Experiments, Instrumental Variables, and Mendelian Randomization (Strengths and Limitations)

The Worst Misinterpretations Ive Seen in Observational Research Studies: How to Spot Them, How to Avoid Them

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Opening Salvo: Despite EXCEL And NOBLE, I Don't Believe PCI Should Be the Standard Revascularization Strategy for Most Patients With Left Main CAD!

Return Fire: The Contrarian View - Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Opening Salvo: I Don't Believe Bioresorbable Scaffolds Provide Meaningful Value for Most Patients Undergoing PCI!

Subgroup Analyses: How Useful or Harmful Are They?

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Limitations of Pharmacotherapy Clinical Trial Design

利拉鲁肽超越 FDA 安全预期，可降低心血管疾病的死亡率：LEADER

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

FDA 与阿玛琳之间的和解是否会减弱该局对标签外用途推广的监督？

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content